Literature DB >> 18269310

Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.

Xiaodong Li1, Michael S Ominsky, Qing-Tian Niu, Ning Sun, Betsy Daugherty, Diane D'Agostin, Carole Kurahara, Yongming Gao, Jin Cao, Jianhua Gong, Frank Asuncion, Mauricio Barrero, Kelly Warmington, Denise Dwyer, Marina Stolina, Sean Morony, Ildiko Sarosi, Paul J Kostenuik, David L Lacey, W Scott Simonet, Hua Zhu Ke, Chris Paszty.   

Abstract

INTRODUCTION: Sclerosteosis is a rare high bone mass genetic disorder in humans caused by inactivating mutations in SOST, the gene encoding sclerostin. Based on these data, sclerostin has emerged as a key negative regulator of bone mass. We generated SOST knockout (KO) mice to gain a more detailed understanding of the effects of sclerostin deficiency on bone.
MATERIALS AND METHODS: Gene targeting was used to inactivate SOST and generate a line of SOST KO mice. Radiography, densitometry, microCT, histomorphometry, and mechanical testing were used to characterize the impact of sclerostin deficiency on bone in male and female mice. Comparisons were made between same sex KO and wildtype (WT) mice.
RESULTS: The results for male and female SOST KO mice were similar, with differences only in the magnitude of some effects. SOST KO mice had increased radiodensity throughout the skeleton, with general skeletal morphology being normal in appearance. DXA analysis of lumbar vertebrae and whole leg showed that there was a significant increase in BMD (>50%) at both sites. microCT analysis of femur showed that bone volume was significantly increased in both the trabecular and cortical compartments. Histomorphometry of trabecular bone revealed a significant increase in osteoblast surface and no significant change in osteoclast surface in SOST KO mice. The bone formation rate in SOST KO mice was significantly increased for trabecular bone (>9-fold) at the distal femur, as well as for the endocortical and periosteal surfaces of the femur midshaft. Mechanical testing of lumbar vertebrae and femur showed that bone strength was significantly increased at both sites in SOST KO mice.
CONCLUSIONS: SOST KO mice have a high bone mass phenotype characterized by marked increases in BMD, bone volume, bone formation, and bone strength. These results show that sclerostin is a key negative regulator of a powerful, evolutionarily conserved bone formation pathway that acts on both trabecular and cortical bone.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18269310     DOI: 10.1359/jbmr.080216

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  372 in total

1.  Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading.

Authors:  Xiaolin Tu; Yumie Rhee; Keith W Condon; Nicoletta Bivi; Matthew R Allen; Denise Dwyer; Marina Stolina; Charles H Turner; Alexander G Robling; Lilian I Plotkin; Teresita Bellido
Journal:  Bone       Date:  2011-10-30       Impact factor: 4.398

2.  Circulating sclerostin in disorders of parathyroid gland function.

Authors:  Aline G Costa; Serge Cremers; Mishaela R Rubin; Donald J McMahon; James Sliney; Marise Lazaretti-Castro; Shonni J Silverberg; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2011-09-21       Impact factor: 5.958

Review 3.  Update on Wnt signaling in bone cell biology and bone disease.

Authors:  David G Monroe; Meghan E McGee-Lawrence; Merry Jo Oursler; Jennifer J Westendorf
Journal:  Gene       Date:  2011-11-03       Impact factor: 3.688

Review 4.  Osteocyte regulation of bone mineral: a little give and take.

Authors:  G J Atkins; D M Findlay
Journal:  Osteoporos Int       Date:  2012-08       Impact factor: 4.507

Review 5.  Osteoblastogenesis regulation signals in bone remodeling.

Authors:  C Zuo; Y Huang; R Bajis; M Sahih; Y-P Li; K Dai; X Zhang
Journal:  Osteoporos Int       Date:  2012-06       Impact factor: 4.507

Review 6.  Inflammatory bone loss: pathogenesis and therapeutic intervention.

Authors:  Kurt Redlich; Josef S Smolen
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

Review 7.  Catabolic and anabolic actions of parathyroid hormone on the skeleton.

Authors:  B C Silva; A G Costa; N E Cusano; S Kousteni; J P Bilezikian
Journal:  J Endocrinol Invest       Date:  2011-09-23       Impact factor: 4.256

Review 8.  Wnt signaling in cardiovascular disease: opportunities and challenges.

Authors:  Austin Gay; Dwight A Towler
Journal:  Curr Opin Lipidol       Date:  2017-10       Impact factor: 4.776

9.  Implant-derived magnesium induces local neuronal production of CGRP to improve bone-fracture healing in rats.

Authors:  Yifeng Zhang; Jiankun Xu; Ye Chun Ruan; Mei Kuen Yu; Micheal O'Laughlin; Helen Wise; Di Chen; Li Tian; Dufang Shi; Jiali Wang; Sihui Chen; Jian Q Feng; Dick Ho Kiu Chow; Xinhui Xie; Lizhen Zheng; Le Huang; Shuo Huang; Kwoksui Leung; Na Lu; Lan Zhao; Huafang Li; Dewei Zhao; Xia Guo; Kaiming Chan; Frank Witte; Hsiao Chang Chan; Yufeng Zheng; Ling Qin
Journal:  Nat Med       Date:  2016-08-29       Impact factor: 53.440

Review 10.  WNT signaling in bone homeostasis and disease: from human mutations to treatments.

Authors:  Roland Baron; Michaela Kneissel
Journal:  Nat Med       Date:  2013-02-06       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.